First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Could RO7851624, newly into clinical trials, be RG6735?
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
No sooner does one gammadelta-focused biotech die than another takes its place.
